Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Therapies in development for castrate-resistant prostate cancer.

Harzstark AL, Ryan CJ.

Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi: 10.1586/14737140.8.2.259. Review.

PMID:
18279066
2.

Activity of epothilone B analogues ixabepilone and patupilone in hormone-refractory prostate cancer.

Lee D.

Clin Prostate Cancer. 2004 Sep;3(2):80-2. Review. No abstract available.

PMID:
15479489
3.

Emerging therapies in castrate-resistant prostate cancer.

Lassi K, Dawson NA.

Curr Opin Oncol. 2009 May;21(3):260-5. doi: 10.1097/CCO.0b013e32832a1868. Review.

PMID:
19363343
4.

Update in systemic therapy of prostate cancer: improvement in quality and duration of life.

Vaishampayan U, Hussain M.

Expert Rev Anticancer Ther. 2008 Feb;8(2):269-81. doi: 10.1586/14737140.8.2.269. Review.

PMID:
18279067
5.

Second-line chemotherapy for advanced hormone-refractory prostate cancer.

Garmey EG, Sartor O, Halabi S, Vogelzang NJ.

Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32. Review.

PMID:
18347563
6.

Novel therapeutic strategies in development for prostate cancer.

Harzstark AL, Ryan CJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):13-22. Review.

PMID:
18095915
7.

Maximal androgen blockade for advanced prostate cancer.

Klotz L.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004. Review.

PMID:
18471790
8.

Benefit of extended zoledronate therapy for patients with bone metastases from hormone-refractory prostate cancer.

Price N.

Clin Prostate Cancer. 2004 Sep;3(2):77-9. Review. No abstract available.

PMID:
15479488
9.

Chemotherapy for recurrent cervical cancer.

Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E.

Cancer Treat Rev. 2008 Nov;34(7):603-13. doi: 10.1016/j.ctrv.2008.05.006. Epub 2008 Jul 26. Review.

PMID:
18657909
10.

Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?

Akaza H.

Can J Urol. 2005 Feb;12 Suppl 1:77-80. Review.

PMID:
15780172
11.

Therapeutic vaccines for prostate cancer.

Cha E, Fong L.

Curr Opin Mol Ther. 2010 Feb;12(1):77-85. Review.

PMID:
20140819
12.

Current clinical trials in castrate-resistant prostate cancer.

Petrylak DP.

Curr Urol Rep. 2011 Jun;12(3):173-9. doi: 10.1007/s11934-011-0187-z. Review.

PMID:
21533748
13.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G.

Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11. Review.

PMID:
18620815
14.

Treatment options in hormone resistant prostate cancer.

De Mulder PH, Schalken JA, Sternberg CN.

Ann Oncol. 2002;13 Suppl 4:95-102. Review. No abstract available.

PMID:
12401673
15.

[Early versus late hormonal treatment in advanced prostate cancer].

Allepuz Losa C, Gil Martínez P, Gil Sanz MJ, Rioja Sanz LA.

Actas Urol Esp. 1999 Jul-Aug;23(7):557-64. Review. Spanish. No abstract available.

PMID:
10488608
16.

New treatment developments applied to elderly patients with advanced prostate cancer.

Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS.

Cancer Treat Rev. 2013 Oct;39(6):578-83. doi: 10.1016/j.ctrv.2012.12.004. Epub 2013 Jan 3. Review.

PMID:
23290885
17.

Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.

Moreno-Aspitia A, Perez EA.

Clin Ther. 2009 Aug;31(8):1619-40. doi: 10.1016/j.clinthera.2009.08.005. Review.

PMID:
19808124
18.

Immunotherapy for prostate cancer - recent progress in clinical trials.

Kipp RT, McNeel DG.

Clin Adv Hematol Oncol. 2007 Jun;5(6):465-74, 477-9. Review.

PMID:
17679921
19.

Immunotherapeutics in development for prostate cancer.

Harzstark AL, Small EJ.

Oncologist. 2009 Apr;14(4):391-8. doi: 10.1634/theoncologist.2008-0240. Epub 2009 Apr 2. Review.

20.

Epothilones and the next generation of phase III trials for prostate cancer.

Bhandari MS, Hussain M.

BJU Int. 2005 Aug;96(3):296-302. Review. No abstract available.

Supplemental Content

Support Center